Search

We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine (Sinovac) and BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). We compared rates of antibody waning over time using an enzyme-linked immunosorbent assay for spike receptor binding domain and a surrogate virus neutralization test. We found stronger and more durable antibody responses to two doses of the mRNA vaccine, and slightly stronger initial antibody responses to each vaccine in younger adults and women. The weaker and less durable responses following CoronaVac support earlier provision of third doses to persons who previously received two doses of this vaccine., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘Ben Cowling reports a relationship with Fosun Pharma USA Inc that includes: consulting or advisory. Ben Cowling reports a relationship with AstraZeneca that includes: consulting or advisory. Ben Cowling reports a relationship with GSK that includes: consulting or advisory. Ben Cowling reports a relationship with Moderna Therapeutics Inc that includes: consulting or advisory. Ben Cowling reports a relationship with Pfizer that includes: consulting or advisory. Ben Cowling reports a relationship with Roche that includes: consulting or advisory. Ben Cowling reports a relationship with Sanofi Pasteur that includes: consulting or advisory. BJC consults for AstraZeneca, Fosun Pharma, GSK, Moderna, Pfizer, Roche and Sanofi Pasteur. The authors report no other potential conflicts of interest.’., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)